Class 3 Medicines Recall: Accord-UK Ltd, Digoxin Tablets BP 250 micrograms, EL (20)A/35
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Source · Drug & device safety alerts
MHRA Drug & Device Safety Alerts
1,501 individual alerts
447 medicines recalls & defect notices
766 weekly / monthly index pages
Oct 2009 – Jul 2026
Drug safety updates, medicines recalls, device safety information and field safety notices published by the Medicines and Healthcare products Regulatory Agency. Source: MHRA alerts and recalls on GOV.UK.
Showing 2,267 publications of 2,267
Medical Device Alerts issued in June 2020
A periodic index page listing other alerts and letters, not a single alert.
Letters and drug alerts sent to healthcare professionals in June 2020
A periodic index page listing other alerts and letters, not a single alert.
Liposomal and lipid-complex formulations: name change to reduce medication errors
An article in MHRA's monthly Drug Safety Update bulletin.
Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
An article in MHRA's monthly Drug Safety Update bulletin.
Class 2 Medicines Recall: Kyowa Kirin Limited, Abstral 200 microgram sublingual tablets, EL (20)A/34
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices - 20 July - 24 July 2020
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Pfizer Limited, Ecalta 100mg powder for concentrate for solution for infusion, EL (20)A/32
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Philips sterilizable defibrillator internal paddles (specific models) – may fail to deliver therapy if pre-use checks are not followed (MDA/2020/022)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Class 3 Medicines Recall: Accord Healthcare Limited, Irinotecan Hydrochloride Concentrate for Solution for Infusion 20mg/ml (5ml vial), EL (20)A/33
MHRA class: the defect is unlikely to cause harm; recall is on other grounds.
Class 4 Medicines Defect Information: Aspar Pharmaceuticals Limited, Ibuprofen 200mg and 400mg tablets packaged in various liveries, EL (20)A/30
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Defect Information: Ennogen Pharma Limited, Trimogal 100mg and 200mg Tablets, EL (20)A/31
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Field Safety Notices - 13 July to 17 July 2020
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Nitrofurantoin 50 mg Tablets, PL 08553/0087, EL (20)A/28
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 2 Medicines Recall: Ferring Pharmaceuticals Limited, desmopressin nasal spray (all strengths), PL 03194/0024, PL 03194/0090, PL 03194/0056, EL (20)A/29
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices - 06 July to 10 July 2020
A weekly index of the field safety notices manufacturers issued that week.
Spinal fixation system – risk of implant failure prior to completion of bone healing (MDA/2020/020)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Field Safety Notices - 29 June to 03 July 2020
A weekly index of the field safety notices manufacturers issued that week.
Abbott Trifecta / Trifecta GT bioprosthetic aortic heart valves: cases of structural valve deterioration (SVD) (MDA/2020/019)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Class 2 Medicines Recall: Mepacrine Hydrochloride 100 mg Tablets (Batch 85641), EL (20)A/27
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Class 4 Medicines Defect Information: Depo-Provera 150mg/ml Injection (1ml Vial) EL (20)A/26
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Philips HeartStart XL Defibrillator/Monitor – therapy selector switch may fail (MDA/2020/018)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Field Safety Notices - 22 June to 26 June 2020
A weekly index of the field safety notices manufacturers issued that week.
Letters and drug alerts sent to healthcare professionals in May 2020
A periodic index page listing other alerts and letters, not a single alert.
Cyproterone acetate: new advice to minimise risk of meningioma
An article in MHRA's monthly Drug Safety Update bulletin.
Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices - 15 to 19 June 2020
A weekly index of the field safety notices manufacturers issued that week.
Philips HeartStart MRx Monitor/Defibrillators - may fail to deliver therapy without alerting the user to a fault in the event of internal damage (MDA/2020/016)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Field Safety Notices - 08 to 12 June 2020
A weekly index of the field safety notices manufacturers issued that week.
Results from laboratory-based tests for COVID-19 antibodies using capillary blood sample collection kits may not be reliable (MDA/2020/015)
Medical Device Alert (MDA): the format MHRA used for device alerts until 2021.
Class 2 Medicines Recall: Epistatus (Midazolam) 10mg/mL Oromucosal Solution (Multi Dose Bottles), EL (20)A/25
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices - 01 to 05 June 2020
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices - 27 to 29 May 2020
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices - 18 to 22 May 2020
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Sodium Benzoate (Amzoate) 2g in 10 mL Sterile Solution for injection, EL (20)A/24
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Company led drug alert - Duavive (conjugated oestrogen/bazedoxifene acetate) 0.45mg/20mg Modified Release Tablets – EU/1/14/960/001
A recall the marketing authorisation holder initiated, published by MHRA.
Letters and drug alerts sent to healthcare professionals in April 2020
A periodic index page listing other alerts and letters, not a single alert.
Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)
An article in MHRA's monthly Drug Safety Update bulletin.
Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices
An article in MHRA's monthly Drug Safety Update bulletin.
Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)
An article in MHRA's monthly Drug Safety Update bulletin.
Field Safety Notices - 11 to 15 May 2020
A weekly index of the field safety notices manufacturers issued that week.
Class 2 Medicines Recall: Emerade 500 micrograms solution for injection in pre-filled syringe, PL 33616/0015 (EL(20)A/23
MHRA class: the defect could cause illness or mistreatment, but is not Class 1.
Field Safety Notices - 4 to 8 May 2020
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices - 27 April to 1 May 2020
A weekly index of the field safety notices manufacturers issued that week.
Field Safety Notices - 20 to 24 April 2020
A weekly index of the field safety notices manufacturers issued that week.
Coronavirus (COVID-19): latest guidance for medicines safety
An article in MHRA's monthly Drug Safety Update bulletin.
Letters and drug alerts sent to healthcare professionals in March 2020
A periodic index page listing other alerts and letters, not a single alert.
Field Safety Notices - 13 to 17 April 2020
A weekly index of the field safety notices manufacturers issued that week.
Class 4 Medicines Defect Information: Glaxosmithkline Consumer Healthcare (UK) Trading Limited, various products, EL(20)A/22
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
Class 4 Medicines Defect Information: Levofloxacin 500mg Tablets, PL 00289/1047 EL (20)A/21
MHRA class: a minor defect; the product stays available with a caution in use, not a recall.
About this source
Individual alerts by type
Read the chart values
| Alert type | Individual alerts |
|---|---|
| Drug Safety Update | 713 |
| Class 1 Medicines Recall | 6 |
| Class 2 Medicines Recall | 159 |
| Class 3 Medicines Recall | 68 |
| Class 4 Medicines Defect Information | 179 |
| Company-Led Medicines Recall | 35 |
| Device Safety Information | 21 |
| Medical Device Alert | 40 |
| National Patient Safety Alert | 11 |
| MHRA Safety Roundup | 16 |
| Unclassified | 253 |
The MHRA regulates medicines and medical devices in the UK and publishes safety communications on GOV.UK in two streams: the monthly Drug Safety Update bulletin, and Alerts and recalls for drugs and medical devices. This page holds 2,267 of those publications, issued between October 2009 and July 2026.
MHRA classes a medicines recall by the hazard the defect presents: Class 1 life-threatening or serious, Class 2 could cause illness or mistreatment, Class 3 unlikely to cause harm, and Class 4 a caution in use rather than a recall, with the product staying available. A device notice is published as Device Safety Information, or, until 2021, as a Medical Device Alert.
What is not here. We hold each publication's title, type, date and link, not its text: read the alert on GOV.UK for the affected products and the actions MHRA asks for. An alert names a medicine or device and a clinical audience, not an organisation, so no alert on this page is linked to an NHS trust or other responsible body. The weekly “Field Safety Notices” pages are MHRA's own index of the notices manufacturers issued that week, not single alerts, and are counted separately above.